United Therapeutics Corporation (FRA:UTH)

Germany flag Germany · Delayed Price · Currency is EUR
415.40
+2.30 (0.56%)
Last updated: Dec 5, 2025, 8:04 AM CET
17.11%
Market Cap 17.87B
Revenue (ttm) 2.67B
Net Income (ttm) 1.08B
Shares Out n/a
EPS (ttm) 22.48
PE Ratio 16.49
Forward PE 14.68
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 12
Open 415.40
Previous Close 413.10
Day's Range 415.40 - 415.40
52-Week Range 237.40 - 424.60
Beta n/a
RSI 60.57
Earnings Date Feb 26, 2026

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr... [Read more]

Industry Pharmaceutical Preparations
Founded 1996
Employees 1,305
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol UTH
Full Company Profile

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Financial numbers in USD Financial Statements

News

There is no news available yet.